DK3125894T3 - Prodrugs af hiv-reverstranscriptasehæmmere - Google Patents
Prodrugs af hiv-reverstranscriptasehæmmere Download PDFInfo
- Publication number
- DK3125894T3 DK3125894T3 DK15774282.6T DK15774282T DK3125894T3 DK 3125894 T3 DK3125894 T3 DK 3125894T3 DK 15774282 T DK15774282 T DK 15774282T DK 3125894 T3 DK3125894 T3 DK 3125894T3
- Authority
- DK
- Denmark
- Prior art keywords
- reverstranscriptase
- hiv
- inhibitors
- products
- reverstranscriptase inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461973689P | 2014-04-01 | 2014-04-01 | |
| PCT/US2015/022868 WO2015153304A1 (en) | 2014-04-01 | 2015-03-27 | Prodrugs of hiv reverse transcriptase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3125894T3 true DK3125894T3 (da) | 2020-11-16 |
Family
ID=54241131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15774282.6T DK3125894T3 (da) | 2014-04-01 | 2015-03-27 | Prodrugs af hiv-reverstranscriptasehæmmere |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10004740B2 (da) |
| EP (2) | EP3785714A1 (da) |
| JP (1) | JP6342011B2 (da) |
| KR (1) | KR102440843B1 (da) |
| CN (1) | CN106456639B (da) |
| AU (1) | AU2015241247B2 (da) |
| BR (1) | BR112016022722B8 (da) |
| CA (1) | CA2944187C (da) |
| CY (1) | CY1123582T1 (da) |
| DK (1) | DK3125894T3 (da) |
| ES (1) | ES2828951T3 (da) |
| HR (1) | HRP20201780T1 (da) |
| HU (1) | HUE051848T2 (da) |
| LT (1) | LT3125894T (da) |
| MX (1) | MX2016012915A (da) |
| PL (1) | PL3125894T3 (da) |
| PT (1) | PT3125894T (da) |
| RS (1) | RS61016B1 (da) |
| RU (1) | RU2693622C2 (da) |
| SI (1) | SI3125894T1 (da) |
| WO (1) | WO2015153304A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3470B1 (ar) | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| RU2693622C2 (ru) | 2014-04-01 | 2019-07-03 | Мерк Шарп И Доум Корп. | Пролекарственные средства ингибиторов обратной транскриптазы вич |
| CN106008362B (zh) * | 2016-05-24 | 2018-08-10 | 杰达维（上海）医药科技发展有限公司 | 一种嘧啶衍生物的制备方法 |
| CA3086303A1 (en) | 2017-12-22 | 2019-06-27 | Sumitomo Chemical Company, Limited | Heterocyclic compound and harmful arthropod controlling agent containing same |
| MA54549A (fr) * | 2018-12-18 | 2022-03-30 | Merck Sharp & Dohme | Dérivés de pyrimidone en tant qu'agents cytotoxiques sélectifs contre des cellules infectées par le vih |
| WO2020171129A1 (ja) | 2019-02-20 | 2020-08-27 | 住友化学株式会社 | エーテル化合物及びそれを含有する有害節足動物防除組成物 |
| CN114026081B (zh) * | 2019-05-22 | 2025-02-11 | 默沙东有限责任公司 | 作为针对hiv感染的细胞的选择性细胞毒性剂的吡啶酮衍生物 |
| CN114364665B (zh) | 2019-07-16 | 2024-12-31 | 百时美施贵宝公司 | 调节白介素的前药 |
| TW202304919A (zh) | 2021-03-31 | 2023-02-01 | 印度商皮埃企業有限公司 | 稠合雜環化合物及其作為害蟲控制劑之用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5519021A (en) | 1992-08-07 | 1996-05-21 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| IT1305313B1 (it) | 1998-07-17 | 2001-05-04 | Colla Paolo | 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1. |
| SE9904045D0 (sv) | 1999-11-09 | 1999-11-09 | Astra Ab | Compounds |
| CL2004000192A1 (es) | 2003-02-07 | 2005-03-18 | Janssen Pharmaceutica Nv | Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja. |
| TW200423930A (en) | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
| TW200505441A (en) | 2003-03-24 | 2005-02-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitorsⅠ |
| EP1608629A1 (en) | 2003-03-24 | 2005-12-28 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
| EP1699777B1 (en) * | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7288942B2 (en) * | 2003-10-02 | 2007-10-30 | Naoyuki Sato | Plasma potential measuring method and apparatus, and plasma potential measuring probe |
| US20050282839A1 (en) | 2004-01-12 | 2005-12-22 | Gilead Sciences, Inc. | Pyrimidyl phosphonate antiviral compounds and methods of use |
| CA2559552A1 (en) * | 2004-03-23 | 2005-09-29 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors |
| US7166738B2 (en) | 2004-04-23 | 2007-01-23 | Roche Palo Alto Llc | Non-nucleoside reverse transcriptase inhibitors |
| DK1742908T3 (da) | 2004-04-23 | 2010-01-18 | Hoffmann La Roche | Ikke nukleosid revers transkriptase inhibitorer |
| EP1831157A2 (en) | 2004-12-22 | 2007-09-12 | Pfizer Limited | Nonnucleoside inhibitors of hiv-1 reverse transcriptase |
| AR057455A1 (es) | 2005-07-22 | 2007-12-05 | Merck & Co Inc | Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica |
| ES2320042T3 (es) | 2005-10-19 | 2009-05-18 | F. Hoffmann-La Roche Ag | Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida. |
| BRPI0617720A2 (pt) | 2005-10-19 | 2011-08-02 | Hoffmann La Roche | compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém |
| US7803940B2 (en) | 2006-11-24 | 2010-09-28 | Takeda Pharmaceutical Company Limited | Heteromonocyclic compound or a salt thereof having strong antihypertensive action, insulin sensitizing activity and the like production thereof and use thereof for prophylaxis or treatment of cardiovascular diseases, metabolic diseases and/or central nervous system diseases |
| MX2009005449A (es) | 2006-11-24 | 2009-06-02 | Takeda Pharmaceutical | Compuesto heteromonociclico y uso del mismo. |
| TW200831085A (en) | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
| US8404253B2 (en) | 2006-12-28 | 2013-03-26 | Newport Laboratories, Inc. | Modified live (JMSO strain) Haemophilus parasuis vaccine |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| AU2008326784B2 (en) | 2007-11-20 | 2014-04-24 | Merck Sharp & Dohme Corp. | Non-nucleoside reverse transcriptase inhibitors |
| CN101918372B (zh) | 2008-01-08 | 2014-03-26 | 默沙东公司 | 用于制备n-取代的羟基嘧啶酮羧酰胺类化合物的方法 |
| CN102971308B (zh) | 2010-03-30 | 2015-02-04 | 默克加拿大有限公司 | 非核苷类逆转录酶抑制剂 |
| US20130040914A1 (en) | 2010-04-08 | 2013-02-14 | Samson M. Jolly | Prodrugs of an hiv reverse transcriptase inhibitor |
| JO3470B1 (ar) * | 2012-10-08 | 2020-07-05 | Merck Sharp & Dohme | مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv |
| RU2693622C2 (ru) | 2014-04-01 | 2019-07-03 | Мерк Шарп И Доум Корп. | Пролекарственные средства ингибиторов обратной транскриптазы вич |
-
2015
- 2015-03-27 RU RU2016142611A patent/RU2693622C2/ru active
- 2015-03-27 PL PL15774282T patent/PL3125894T3/pl unknown
- 2015-03-27 BR BR112016022722A patent/BR112016022722B8/pt active IP Right Grant
- 2015-03-27 PT PT157742826T patent/PT3125894T/pt unknown
- 2015-03-27 EP EP20194453.5A patent/EP3785714A1/en active Pending
- 2015-03-27 JP JP2016559867A patent/JP6342011B2/ja active Active
- 2015-03-27 RS RS20201323A patent/RS61016B1/sr unknown
- 2015-03-27 KR KR1020167030064A patent/KR102440843B1/ko active Active
- 2015-03-27 MX MX2016012915A patent/MX2016012915A/es active IP Right Grant
- 2015-03-27 LT LTEP15774282.6T patent/LT3125894T/lt unknown
- 2015-03-27 ES ES15774282T patent/ES2828951T3/es active Active
- 2015-03-27 HU HUE15774282A patent/HUE051848T2/hu unknown
- 2015-03-27 AU AU2015241247A patent/AU2015241247B2/en active Active
- 2015-03-27 EP EP15774282.6A patent/EP3125894B1/en active Active
- 2015-03-27 HR HRP20201780TT patent/HRP20201780T1/hr unknown
- 2015-03-27 WO PCT/US2015/022868 patent/WO2015153304A1/en not_active Ceased
- 2015-03-27 SI SI201531408T patent/SI3125894T1/sl unknown
- 2015-03-27 CA CA2944187A patent/CA2944187C/en active Active
- 2015-03-27 US US15/300,405 patent/US10004740B2/en active Active
- 2015-03-27 CN CN201580029171.XA patent/CN106456639B/zh active Active
- 2015-03-27 DK DK15774282.6T patent/DK3125894T3/da active
-
2020
- 2020-11-11 CY CY20201101068T patent/CY1123582T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| PL3848163T3 (pl) | Zespół pojemników | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
| DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3223805T3 (da) | Prodrugs af phenolisk trpv1-agonister | |
| DK3125894T3 (da) | Prodrugs af hiv-reverstranscriptasehæmmere | |
| HUE053240T2 (hu) | Gemcitabin prodrugok | |
| DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
| DK3132009T3 (da) | Fremgangsmåde | |
| DK3220891T3 (da) | Sublingual formulering af riluzol | |
| DK3283210T3 (da) | Fremgangsmåde | |
| DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
| DK3204352T3 (da) | Hæmmere af lysin-gingipain | |
| DK3418273T3 (da) | Derivater af flavagliner | |
| DK3511000T3 (da) | Krystallinsk form x2 af grapiprant | |
| DK3294287T3 (da) | Oxabicycloheptan-prodrugs | |
| DK3234058T3 (da) | Pakker af metalbeholdere | |
| DK3201323T3 (da) | Modificering af bakteriofag | |
| DK3356235T3 (da) | Fremgangsmåde til dannelse af grupper af røgartikler |